Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. decreased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 16.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,687 shares of the biotechnology company’s stock after selling 7,209 shares during the period. E Fund Management Co. Ltd.’s holdings in Ironwood Pharmaceuticals were worth $431,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Signaturefd LLC boosted its stake in Ironwood Pharmaceuticals by 61.4% in the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 822 shares in the last quarter. SummerHaven Investment Management LLC grew its stake in Ironwood Pharmaceuticals by 1.4% during the 4th quarter. SummerHaven Investment Management LLC now owns 68,745 shares of the biotechnology company’s stock worth $786,000 after buying an additional 980 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in Ironwood Pharmaceuticals by 10.7% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 15,330 shares of the biotechnology company’s stock worth $175,000 after buying an additional 1,483 shares during the period. Daiwa Securities Group Inc. lifted its stake in Ironwood Pharmaceuticals by 331.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ironwood Pharmaceuticals by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,997 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,961 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Piper Sandler upped their price target on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Craig Hallum started coverage on Ironwood Pharmaceuticals in a report on Wednesday, January 17th. They set a “buy” rating and a $21.00 price objective on the stock. Wells Fargo & Company decreased their target price on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Finally, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.80.

Ironwood Pharmaceuticals Stock Down 17.0 %

Shares of Ironwood Pharmaceuticals stock traded down $1.38 on Thursday, hitting $6.74. The company’s stock had a trading volume of 7,358,206 shares, compared to its average volume of 4,219,038. The firm has a fifty day moving average price of $8.40 and a 200-day moving average price of $10.58. Ironwood Pharmaceuticals, Inc. has a 52-week low of $6.21 and a 52-week high of $15.70. The company has a market capitalization of $1.06 billion, a P/E ratio of -1.04 and a beta of 0.57.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, SVP Andrew Davis sold 9,846 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the completion of the transaction, the senior vice president now directly owns 208,324 shares of the company’s stock, valued at approximately $3,174,857.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Jon R. Duane purchased 6,920 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $8.70 per share, with a total value of $60,204.00. Following the purchase, the director now directly owns 121,028 shares of the company’s stock, valued at $1,052,943.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew Davis sold 9,846 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the completion of the transaction, the senior vice president now directly owns 208,324 shares of the company’s stock, valued at approximately $3,174,857.76. The disclosure for this sale can be found here. Insiders have sold 273,008 shares of company stock valued at $4,160,642 over the last quarter. Corporate insiders own 13.10% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.